Insmed reported $125.25M in Current Liabilities for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
DBV Technologies DBVT:US 26.03M 5.37M
Acelrx Pharmaceuticals ACRX:US $ 17.03M 1.48M
Alimera Sciences ALIM:US $ 17.01M 4.41M
Biomarin Pharmaceutical BMRN:US $ 490.42M 49.4M
Cytokinetics CYTK:US $ 66.85M 5.01M
Dynavax Technologies DVAX:US $ 466.2M 90.2M
Gilead Sciences GILD:US $ 8558M 3052M
Heron Therapeutics HRTX:US $ 93M 21.94M
Insmed INSM:US $ 125.25M 9.92M
Mirati Therapeutics MRTX:US $ 123.57M 20.09M
Novartis NVS:US $ 29807M 401M
Ophthotech OPHT:US $ 19.17M 9.04M
Regeneron Pharmaceuticals REGN:US $ 3007.6M 924.9M
Sarepta Therapeutics SRPT:US $ 454.96M 2.23M
Seattle Genetics SGEN:US $ 531.29M 37.56M
Ultragenyx Pharmaceutical RARE:US $ 167.23M 14.14M
Vertex Pharmaceuticals VRTX:US $ 2180.2M 38.2M